• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Our Team

o2h ventures team are leaders in the biotech community and have been actively involved as investors, holding various industry positions for over 20 years.

o2h-ventures

Sunil Shah

CEO

Sunil's Biography

o2h-ventures
close

Sunil Shah

CEO

Sunil Shah is an entrepreneur having begun his career in the Life Sciences team at PA Consulting. He co-founded Oxygen Healthcare Ltd which was fully acquired by Piramal Enterprises Ltd (BSE: PEL) in 2013. Since this time, Sunil has co-founded the o2h Group, this includes o2h Ventures, an HMRC approved ‘Human Health’ Knowledge Intensive EIS fund; o2h Discovery, a medicinal chemistry research services company and o2h Co-Work Labs, a 2.7Acre Science Park under development in South Cambridge. Sunil has won the UKBAA Angel Investor of the year award in 2019 as well as the OBN Special Recognition Award for his significant contribution in the Life Sciences Industry. He serves on the Board of the BIA as well as Cambridge Angels. Recently, Sunil has also won the CEO of the year award at the Cambridge Independent Science and Technology Awards. He is either Chairman, Non-Executive Director, Board Observer or an investor in over 20 Biotech companies in the UK. Sunil has a degree in Biochemistry from Keele and an MBA from Cambridge University.

o2h-ventures

Prashant Shah

Managing Partner

Prashant's Biography

o2h-ventures
close

Prashant Shah

Managing Partner

o2h Ventures was co-founded by Sunil and Prashant Shah in 2013. In the last 3-4 years, they have co-founded four companies with UK-based academics and entrepreneurs, provided consultancy services to five companies, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early-stage investments, and executed early-stage drug discovery research projects for fifteen different companies. In 2013, bucking a pattern of UK Science going to the USA for funding, Sunil and Prashant acted quickly to lead an academic spin out from the USA with promising data in brain cancer and proceeded to run, externally fund and locate that company, Opal Oncology, in the UK. It provided direct hands-on experience of making the scientific decisions and managing the operations of a therapeutics company.

o2h-ventures

Andy Morley

Principal

Andy's Biography

o2h-ventures
close

Andy Morley

Principal

Andy is a Medicinal Chemist with over 25 years of experience working in major pharma (Sanofi-Aventis, AZ). He has experience across all discovery phases, having supported five candidates into the clinic. He is the author and inventor of over 55 publications and patents. Andy has been working full-time with o2h Ventures since 2013, leading the scientific evaluation of investments and providing scientific support on key projects within the portfolio. He is currently the CSO of Opal Oncology and had previously served as CSO for two o2h early-stage collaborations.
 
 

o2h-ventures

Gayatri Shah

Human Capital Advisor

Gayatri's Bio

o2h-ventures
close

Gayatri Shah

Human Capital Advisor

Gayatri Shah has nearly two decades of experience within the search industry, having worked in the UK, USA, and India. She started her search career with Egon Zehnder in India, where she worked for the top 25 Indian Pharma companies, before spending 3 years specialising in finance roles within FTSE 250 organisations at Michael Page in the UK.Prior to founding Tamarind, she was the Principal at BSG Team Ventures (offices in Boston and London), focusing on human capital needs for Venture Capitalist backed biotech start-ups working mainly on cross-border roles between the USA and EU. She is also a board member of Plugin Recruiter, a video recruitment platform start-up based in Cambridge, UK.Gayatri holds a BA (Hons) in Economics from Delhi University and an MSc in Economics from Lancaster University, UK.

o2h-ventures

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary's Biography

o2h-ventures
close

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary Pitts MA(Oxon), MA(London), MBA, FInstLM, FCMI, ACSI is a senior compliance professional of 28 year's standing, a former regulator, Head of Compliance for hedge fund Brevan Howard, Head of Compliance for Europe, Mid-East, Africa and Japan for a boutique investment bank. He is a former director of regulated firms in the UK and South Africa and has been an FCA regulated person since 2001, as well as having fulfilled regulated roles in Ireland.Gary is the founder of Tetractys Partners LLP based in London, a compliance consultancy set up in 2013 which acts for asset managers, hedge funds, brokers, fintechs and consumer credit firms, as well as delivering an extensive range of public and in-house technical training courses. He is also founder and CEO of Tetractys Ireland Limited, its Irish affiliate offering similar services to the Irish market.

o2h-ventures

Dr Chris Torrance

Independent Representative of the Investment Advisory Panel

Dr Chris Torrance Biography

o2h-ventures
close

Dr Chris Torrance

Independent Representative of the Investment Advisory Panel

Chris is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of new and improved ‘Personalized Medicines’, including the identification of novel drug targets for pharmaceutical development. By 2014 Chris and his colleagues had built Horizon into the fastest growing Biotech company in the UK. In the same year, the company listed on the London Stock Exchange with over 100 commercial and scientific staff and significant deal flow with the pharmaceutical Industry, for which Horizon received the Queens Award for International Trade in 2012. Chris completed his post-doctoral training in the laboratory of Professor Bert Vogelstein at the Johns Hopkins University (U.S.A).

o2h-ventures

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine Beech Biography

o2h-ventures
close

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine has over 25 years of experience in biotech, pharmaceutical and as a venture investor. She is currently the CEO of Exonate for which she was one of the founders leading the spin-out from Nottingham University. Catherine has a degree in medicine from Birmingham University and in 2008 was awarded the OBE for services to technology and innovation.

o2h-ventures

Cengiz Tarhan

Independent Representative of the Investment Advisory Panel

Cengiz Tarhan Biography

o2h-ventures
close

Cengiz Tarhan

Independent Representative of the Investment Advisory Panel

Cengiz set up FreeMedic PLC in 1993 which he grew over 25 years and is now known as UCL Business PLC, one of the most prolific and successful technology groups in the UK serving UCL and its associated partner hospitals. Over those years Cengiz was directly involved in many licenses and spinouts including PolyMASC Pharmaceuticals PLC, one of the first university spinouts to float on the London AIM in 1995, Medic to Medic Ltd which was sold to Informa PLC in 2005 and Stanmore Implants Wordwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008. More recently UCLB has been at the vanguard of creating the most promising cancer and gene therapy biotechs in the UK including three.

o2h-ventures

R G Boyle

Independent Representative of the Investment Advisory Panel

Robert's Biography

o2h-ventures
close

R G Boyle

Independent Representative of the Investment Advisory Panel

R G Boyle is a founder and the CEO of Sentinel Oncology Ltd, a company dedicated towards the discovery of novel small molecules for the treatment of unmet medical needs.  Robert is a medicinal chemist by background with over twenty-five years’ industrial experience.  He has held positions at Pfizer (1993-1997); Cambridge Discovery Chemistry (1997-2000); Millennium Pharmaceuticals (200-2003); Astex Therapeutics (2003-2005) & Sentinel Oncology (2005-present).  As CEO & founder of Sentinel Oncology, he has successfully raised multiple rounds of funding, built a pipeline of small molecule drug assets and secured multiple licensing deals with Biotech and Pharma.  Sentinel has been the recipient of numerous awards & grants for innovation and Robert is a named inventor on over 50 patents & publications describing the discovery and use of small molecules for the treatment of unmet medical needs.

o2h-ventures

Tim Sparey

Independent Representative of the Investment Advisory Panel

Tim Sparey Biography

o2h-ventures
close

Tim Sparey

Independent Representative of the Investment Advisory Panel

Tim is an experienced biotech and pharmaceutical leader with a strong track record in executive (Exec Chair, CEO, CBO) and board roles. A founder with over 40 patents and publications, he has successfully led companies through key growth phases, securing over $6 billion in deals, including M&A, licensing, and collaborations. His expertise spans drug discovery, business development, fundraising, and strategic advisory across oncology, CNS, cardiometabolic, AI/ML, inflammation, and vaccines. Tim is known for pioneering innovative R&D approaches and building high-performing cross-functional teams to drive biotech success.

o2h-ventures

Chris Reid

Venture Partner

Chris's Biography

o2h-ventures
close

Chris Reid

Venture Partner

Chris Reid worked in the City for 17 years as a successful equity research analyst and a fund manager. Amongst other achievements, he built a UK Income fund from scratch to be one of the best performing funds in the sector (150% total return in six years) with over £1bn AUM. Prior to joining the City, he spent 6 years as a Technology Consultant at PA Consultants, focusing on evaluation and support of new products and businesses. He has first-hand experience of over 200 businesses in all industries from mining to high-technology manufacturing across the UK, US and Europe and a deep understanding of the financial, strategic and operational factors that must all come together to ensure a successful, financially rewarding investment. He has a Cambridge MA in Natural Sciences (Materials Science) and an MBA from London Business School.

o2h-ventures

Jeff Roix

Venture Partner

Jeff's Biography

o2h-ventures
close

Jeff Roix

Venture Partner

Jeff is a scientist and biotech entrepreneur with over 15 years of experience in discovering medicines. Most recently, he was founder and CEO of NeoPhore Ltd, a UK cancer immunotherapy biotech making small-molecule drugs in DNA damage repair. Prior to that, he worked as COO to establish PhoreMost, a Cambridge University spinout company making therapeutics for “undruggable” targets across many diseases.Jeff’s longer experience in translational and early drug discovery spans US organisations across venture, biotech, pharma and academic science. Jeff obtained his bachelors from the Harvard Extension School, with further training and expertise in the genetics and cell biology of cancer, diabetes and metabolic disease.

o2h-ventures

Riddhi Ahuja

Senior Fund Operations Manager

Riddhi's Biography

o2h-ventures
close

Riddhi Ahuja

Senior Fund Operations Manager

Riddhi is the Senior Fund Operations Manager at o2h ventures and also the EA to CEO. She acts as a liaison for fund-related matters and looks out for deal flow that comes in from prospective investee companies. She has extensive experience as an operations and international business manager in a reputed manufacturing firm. Riddhi has expertise in the field of business administration, marketing, finance and international business management. She has a bachelor’s degree in Business Administration from ICFAI university..

o2h-ventures

Ajit Singh Guller

Marketing Manager

Ajit's Biography

o2h-ventures
close

Ajit Singh Guller

Marketing Manager

As o2h Group’s Marketing Manager, Ajit leads a team of bright marketing professionals focused on strengthening the o2h group brand in the industry and spotting business growth opportunities. Ajit is responsible for brand marketing, advertising and research, content and digital marketing, business analytics, PR and communications.Prior to joining o2h Group, Ajit worked as a digital marketer for two SME tech companies with global client bases and a seed stage ecommerce startup. He is an experienced professional with an eye for design, user experience and behaviour, and digital analytics.

o2h-ventures

Chris White

Vice President, Business Development

o2h-ventures
close

Chris White

Vice President, Business Development

Chris leads fundraising for the o2h human health EIS and SEIS funds, bringing a wealth of experience in business development across the financial services sector. Before joining o2h Ventures, he worked with an independent provider specialising in EIS/SEIS analysis and tax-advantaged investments. His diverse background includes roles in financial media and renewable energy financing. Chris holds a degree in French and European Studies from Aston University.

o2h-ventures

Juhi Shah

Marketing Manager - o2h Ventures

Juhi's biography

o2h-ventures
close

Juhi Shah

Marketing Manager - o2h Ventures

Juhi is the Marketing Manager at o2h Ventures, overseeing the entire marketing lifecycle. She is responsible for curating various marketing content which includes blogs, social media, and websites to generate organic as well as paid traffic and contribute to the company’s revenue. She has previous experience working in the financial and accounting sectors prior to joining o2h Ventures. She has a master's degree in business administration from PDEU University.

o2h-ventures

Shubham Tiwari

Deal Flow Manager

o2h-ventures
close

Shubham Tiwari

Deal Flow Manager

Shubham holds the position of Deal Flow Manager at o2h Ventures, where he plays a vital role in the management and expansion of our investment portfolio. His educational background includes a master's degree in biotechnology, which provides him with a strong domain knowledge essential for evaluating the feasibility of investment opportunities. He has prior experience as a healthcare research analyst, where he developed his skills in competitive intelligence, market estimation, and segmentation.

Speak to a member of our team
Contact Us
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)